Developer docs
API playgroundTry for free, no card

Search company profiles

Krystal Biotech

Full company profile

uuid00022tg

Namestring
Krystal Biotech
Legal namestring
Krystal Biotech, Inc.
Websiteurl
krystalbio.com
Company typeenum
Public
Founded yearint
2016
Descriptiontext

Krystal Biotech is a commercial-stage biotechnology company that develops and commercializes redosable gene therapies for rare and severe genetic diseases. Its lead product, VYJUVEK (beremagene geperpavec-svdt), is the first and only FDA-approved redosable gene therapy and is indicated for dystrophic epidermolysis bullosa (DEB), a devastating skin-fragility disorder caused by COL7A1 mutations. The company was co-founded in 2016 by Krish S. Krishnan (Chairman & CEO) and Suma Krishnan (President of R&D) and is headquartered in Pittsburgh, PA, with operations listed across the US, Germany, France, Japan, Switzerland, and the UK.

The company's technology is built on an engineered replication-deficient HSV-1 viral vector platform that delivers genetic payloads episomally without integration risk. The platform supports payloads exceeding 30kb (VYJUVEK alone carries over 19kb), exhibits broad cell tropism across keratinocytes, fibroblasts, and lung/eye tissue, and evades host immunity to enable repeat dosing—a property most gene therapy vectors lack. Two in-house GMP manufacturing facilities (ASTRA in Sunnyvale and Ancoris in Pittsburgh) provide full vertical integration from virus banks to commercial packaging, supporting sustained gross margins of 94-95%. The platform underpins a pipeline spanning inhaled gene therapies for cystic fibrosis (KB407) and Alpha-1 Antitrypsin Deficiency (KB408), oncology candidates (KB707 in NSCLC and solid tumors), ophthalmology assets (KB801, KB803), and dermatology indications (KB111 for Hailey-Hailey disease), plus a wholly-owned aesthetics subsidiary (Jeune Aesthetics).

Krystal operates a direct commercialization model with a US field sales force targeting dermatologists and healthcare providers, supported by the Krystal Connect patient support program. As of Q1 2026, 570+ unique prescribers had prescribed VYJUVEK and 695+ reimbursement approvals had been secured in the US. Internationally, Krystal has launched through subsidiary operations in Germany, France, Japan, and the UK, and is scaling a global distributor network from 20 to over 40 countries by year-end 2026. Full-year 2025 revenue reached $389.1M (+34% YoY) with $204.8M in net income, and Q1 2026 revenue was $116.4M (+32% YoY), reflecting 11 consecutive quarters of positive EPS and a cash and investments balance of $955.9M.

Short descriptiontext

Krystal Biotech is a commercial-stage biotechnology company that develops redosable gene therapies using a proprietary HSV-1 vector platform, with its lead product VYJUVEK approved for dystrophic epidermolysis bullosa and a broader pipeline across respiratory, oncology, and ophthalmology indications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersPittsburgh, United States
HQ citystring
Pittsburgh
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices7 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
redosable gene therapy, HSV-1 vector platform, rare disease treatment, topical gene therapy, biopharmaceutical products
Industry1 code
PRIMARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biopharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1VYJUVEK Product Sales
TypeOne Time License
Description

Krystal Biotech generates product revenue from sales of VYJUVEK (beremagene geperpavec-svdt), an FDA-approved gene therapy for dystrophic epidermolysis bullosa. The therapy is administered as a topical treatment. Revenue has shown strong growth with 34% year-over-year increase to $389.1 million in 2025, and Q1 2026 revenue of $116.4 million representing 32% year-over-year growth. The company operates on a traditional pharmaceutical commercial model with direct sales force and reimbursement approvals.

seekingalpha.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure, Supply Chain
Pricing details1 tier
1VYJUVEK treatment pricing - not publicly disclosed
ModelOtherBilling cadenceMulti-year contract
Notes

VYJUVEK pricing is quote-based and not publicly disclosed. The company secures reimbursement approvals and works with insurance providers and government payers on coverage.

in.investing.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1VYJUVEK
Description

First and only redosable gene therapy for the treatment of dystrophic epidermolysis bullosa (DEB). Contains beremagene geperpavec-svdt for topical application.

krystalbio.com
+1 more record
Core offering1 text field

Krystal Biotech develops, manufactures, and commercializes redosable genetic medicines using its proprietary engineered replication-deficient HSV-1 vector platform. The lead commercial product is VYJUVEK (beremagene geperpavec-svdt), the first and only FDA-approved redosable gene therapy for dystrophic epidermolysis bullosa (DEB), applied topically to deliver the COL7A1 gene to skin cells. The company also maintains a pipeline of gene therapy candidates for cystic fibrosis, Alpha-1 Antitrypsin Deficiency, lung cancer, neurotrophic keratitis, and other rare diseases, plus an aesthetics subsidiary (Jeune Aesthetics).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 34% year-over-year revenue growth in 2025 to $389.1 million
+4 more records
Product overview1 text field

Krystal Biotech is a fully integrated, commercial-stage biotechnology company developing redosable genetic medicines using its proprietary HSV-1 gene delivery platform. The company's lead product is VYJUVEK (beremagene geperpavec-svdt), the first and only FDA-approved redosable gene therapy for dystrophic epidermolysis bullosa (DEB). VYJUVEK is approved in the US, Europe, and Japan, with additional approvals in the UK. The platform supports a broad pipeline of candidates across dermatology, respiratory (cystic fibrosis, Alpha-1 Antitrypsin Deficiency), oncology (KB707 for NSCLC and solid tumors), ophthalmology (KB801 for neurotrophic keratitis, KB803 for corneal abrasions), and aesthetics (Jeune Aesthetics subsidiary). The technology enables focal gene delivery with repeat dosing capabilities through engineered HSV-1 vectors that evade host immunity.

Product and service1 record
1VYJUVEK (beremagene geperpavec-svdt)
CategoryGene Therapy / Biopharmaceutical
Description

The first and only FDA-approved redosable gene therapy for the treatment of dystrophic epidermolysis bullosa (DEB), a rare genetic skin disorder caused by mutations in the COL7A1 gene. Contains over 19 kb of genetic cargo and is applied topically to wounds to deliver functional copies of the COL7A1 gene to skin cells.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Gene therapy company developing AAV-based treatments for rare diseases including Huntington's disease and hemophilia. Comparable platform-based rare disease gene therapy model.

TypeBroad incumbent
Description

Major rare disease pharmaceutical company with dominant position in cystic fibrosis (CFTR modulators). Directly overlaps with Krystal's KB407 cystic fibrosis gene therapy program and competes for the same patient population.

TypeBroad incumbent
Description

Large biotechnology company with established gene therapy capabilities and rare disease programs through Regeneron Genetic Medicines. Comparable as a broader rare disease player with gene therapy investment, though operating at much larger scale.

TypeDirect peer
Description

Clinical-stage gene therapy company developing treatments for dystrophic and recessive epidermolysis bullosa, directly overlapping with VYJUVEK's DEB indication. Competes in the same rare dermatology gene therapy space.

TypeBroad incumbent
Description

Established rare disease biotechnology company with multiple approved genetic medicines. Comparable as a commercial-stage rare disease therapeutics company, though with a broader portfolio including enzyme replacement therapies.

TypeDirect peer
Description

Late-stage gene therapy company focused on rare monogenic diseases using lentiviral and AAV platforms. Highly comparable business model of platform-based rare disease gene therapy commercialization.

TypeDirect peer
Description

Commercial-stage gene therapy company with multiple approved rare disease genetic medicines (DMD). Comparable in commercial-stage rare disease gene therapy execution, though focused on AAV-based delivery.

TypeEmerging player
Description

Commercial-stage rare disease company developing genetic medicines including gene therapies. Overlaps in rare disease focus and gene therapy pipeline development.

TypeDirect peer
Description

Pioneer in CRISPR/Cas9 gene-editing therapies with approved products for sickle cell disease and beta thalassemia. Comparable as a genetic medicine platform company targeting rare monogenic diseases, though using a different modality.

10bluebird bio
TypeDirect peer
Description

Gene therapy company developing lentiviral-based treatments for rare genetic diseases. Comparable as a platform-based rare disease gene therapy developer with approved products.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Krystal Biotech

Biopharmaceuticalskrystalbio.com

Krystal Biotech is a commercial-stage biotechnology company that develops redosable gene therapies using a proprietary HSV-1 vector platform, with its lead product VYJUVEK approved for dystrophic epidermolysis bullosa and a broader pipeline across respiratory, oncology, and ophthalmology indications.

What Krystal Biotech does

Krystal Biotech is a commercial-stage biotechnology company that develops and commercializes redosable gene therapies for rare and severe genetic diseases. Its lead product, VYJUVEK (beremagene geperpavec-svdt), is the first and only FDA-approved redosable gene therapy and is indicated for dystrophic epidermolysis bullosa (DEB), a devastating skin-fragility disorder caused by COL7A1 mutations. The company was co-founded in 2016 by Krish S. Krishnan (Chairman & CEO) and Suma Krishnan (President of R&D) and is headquartered in Pittsburgh, PA, with operations listed across the US, Germany, France, Japan, Switzerland, and the UK.

The company's technology is built on an engineered replication-deficient HSV-1 viral vector platform that delivers genetic payloads episomally without integration risk. The platform supports payloads exceeding 30kb (VYJUVEK alone carries over 19kb), exhibits broad cell tropism across keratinocytes, fibroblasts, and lung/eye tissue, and evades host immunity to enable repeat dosing—a property most gene therapy vectors lack. Two in-house GMP manufacturing facilities (ASTRA in Sunnyvale and Ancoris in Pittsburgh) provide full vertical integration from virus banks to commercial packaging, supporting sustained gross margins of 94-95%. The platform underpins a pipeline spanning inhaled gene therapies for cystic fibrosis (KB407) and Alpha-1 Antitrypsin Deficiency (KB408), oncology candidates (KB707 in NSCLC and solid tumors), ophthalmology assets (KB801, KB803), and dermatology indications (KB111 for Hailey-Hailey disease), plus a wholly-owned aesthetics subsidiary (Jeune Aesthetics).

Krystal operates a direct commercialization model with a US field sales force targeting dermatologists and healthcare providers, supported by the Krystal Connect patient support program. As of Q1 2026, 570+ unique prescribers had prescribed VYJUVEK and 695+ reimbursement approvals had been secured in the US. Internationally, Krystal has launched through subsidiary operations in Germany, France, Japan, and the UK, and is scaling a global distributor network from 20 to over 40 countries by year-end 2026. Full-year 2025 revenue reached $389.1M (+34% YoY) with $204.8M in net income, and Q1 2026 revenue was $116.4M (+32% YoY), reflecting 11 consecutive quarters of positive EPS and a cash and investments balance of $955.9M.

Krystal Biotech firmographics

Firmographics
Name
Krystal Biotech
Legal name
Krystal Biotech, Inc.
Website
https://krystalbio.com
Company type
Public
Founded year
2016
Operating status
Operating
Headcount range
251–500 employees
Short description
Krystal Biotech is a commercial-stage biotechnology company that develops redosable gene therapies using a proprietary HSV-1 vector platform, with its lead product VYJUVEK approved for dystrophic epidermolysis bullosa and a broader pipeline across respiratory, oncology, and ophthalmology indications.
Ownership category
akta.pro rank

Krystal Biotech industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Redosable gene therapy
  • HSV-1 vector platform
  • Rare disease treatment
  • Topical gene therapy
  • Biopharmaceutical products

Where Krystal Biotech is headquartered

Location

Headquarters

HQ city
Pittsburgh
HQ country
United States
HQ region
North America

Offices7 records

Markets served

Krystal Biotech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure, Supply Chain

Revenue model

  1. VYJUVEK Product Sales: Krystal Biotech generates product revenue from sales of VYJUVEK (beremagene geperpavec-svdt), an FDA-approved gene therapy for dystrophic epidermolysis bullosa. The therapy is administered as a topical treatment. Revenue has shown strong growth with 34% year-over-year increase to $389.1 million in 2025, and Q1 2026 revenue of $116.4 million representing 32% year-over-year growth. The company operates on a traditional pharmaceutical commercial model with direct sales force and reimbursement approvals.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractVYJUVEK treatment pricing - not publicly disclosed

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Krystal Biotech product offering

Product offering

Core offering

Krystal Biotech develops, manufactures, and commercializes redosable genetic medicines using its proprietary engineered replication-deficient HSV-1 vector platform. The lead commercial product is VYJUVEK (beremagene geperpavec-svdt), the first and only FDA-approved redosable gene therapy for dystrophic epidermolysis bullosa (DEB), applied topically to deliver the COL7A1 gene to skin cells. The company also maintains a pipeline of gene therapy candidates for cystic fibrosis, Alpha-1 Antitrypsin Deficiency, lung cancer, neurotrophic keratitis, and other rare diseases, plus an aesthetics subsidiary (Jeune Aesthetics).

Product overview

Krystal Biotech is a fully integrated, commercial-stage biotechnology company developing redosable genetic medicines using its proprietary HSV-1 gene delivery platform. The company's lead product is VYJUVEK (beremagene geperpavec-svdt), the first and only FDA-approved redosable gene therapy for dystrophic epidermolysis bullosa (DEB). VYJUVEK is approved in the US, Europe, and Japan, with additional approvals in the UK. The platform supports a broad pipeline of candidates across dermatology, respiratory (cystic fibrosis, Alpha-1 Antitrypsin Deficiency), oncology (KB707 for NSCLC and solid tumors), ophthalmology (KB801 for neurotrophic keratitis, KB803 for corneal abrasions), and aesthetics (Jeune Aesthetics subsidiary). The technology enables focal gene delivery with repeat dosing capabilities through engineered HSV-1 vectors that evade host immunity.

Differentiator

Problem solved

Functional benefit

Brands

  • VYJUVEK: First and only redosable gene therapy for the treatment of dystrophic epidermolysis bullosa (DEB). Contains beremagene geperpavec-svdt for topical application.
  • Jeune Aesthetics

Products and services

  • VYJUVEK (beremagene geperpavec-svdt) The first and only FDA-approved redosable gene therapy for the treatment of dystrophic epidermolysis bullosa (DEB), a rare genetic skin disorder caused by mutations in the COL7A1 gene. Contains over 19 kb of genetic cargo and is applied topically to wounds to deliver functional copies of the COL7A1 gene to skin cells.

Quantifiable outcome

  • 34% year-over-year revenue growth in 2025 to $389.1 million
  • +4 more outcomes

Companies that use Krystal Biotech

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Krystal Biotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Krystal Biotech partnerships and signals

Strategic signal

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Krystal Biotech competitors and assessment

Company assessment

Direct peers

  • uniQure: Gene therapy company developing AAV-based treatments for rare diseases including Huntington's disease and hemophilia. Comparable platform-based rare disease gene therapy model.
  • Abeona Therapeutics: Clinical-stage gene therapy company developing treatments for dystrophic and recessive epidermolysis bullosa, directly overlapping with VYJUVEK's DEB indication. Competes in the same rare dermatology gene therapy space.
  • Rocket Pharmaceuticals: Late-stage gene therapy company focused on rare monogenic diseases using lentiviral and AAV platforms. Highly comparable business model of platform-based rare disease gene therapy commercialization.
  • Sarepta Therapeutics: Commercial-stage gene therapy company with multiple approved rare disease genetic medicines (DMD). Comparable in commercial-stage rare disease gene therapy execution, though focused on AAV-based delivery.
  • CRISPR Therapeutics: Pioneer in CRISPR/Cas9 gene-editing therapies with approved products for sickle cell disease and beta thalassemia. Comparable as a genetic medicine platform company targeting rare monogenic diseases, though using a different modality.
  • bluebird bio: Gene therapy company developing lentiviral-based treatments for rare genetic diseases. Comparable as a platform-based rare disease gene therapy developer with approved products.

Broad incumbents

  • Vertex Pharmaceuticals: Major rare disease pharmaceutical company with dominant position in cystic fibrosis (CFTR modulators). Directly overlaps with Krystal's KB407 cystic fibrosis gene therapy program and competes for the same patient population.
  • Regeneron Pharmaceuticals: Large biotechnology company with established gene therapy capabilities and rare disease programs through Regeneron Genetic Medicines. Comparable as a broader rare disease player with gene therapy investment, though operating at much larger scale.
  • BioMarin Pharmaceutical: Established rare disease biotechnology company with multiple approved genetic medicines. Comparable as a commercial-stage rare disease therapeutics company, though with a broader portfolio including enzyme replacement therapies.

Emerging players

  • Ultragenyx Pharmaceutical: Commercial-stage rare disease company developing genetic medicines including gene therapies. Overlaps in rare disease focus and gene therapy pipeline development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Krystal Biotech social profiles

Digital presence

Krystal Biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Krystal Biotech leadership team

Management profile

Number of profiles

Profiles10 records

Krystal Biotech subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Krystal Biotech funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Krystal Biotech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Krystal Biotech

What does Krystal Biotech do?

Krystal Biotech develops, manufactures, and commercializes redosable genetic medicines using its proprietary engineered replication-deficient HSV-1 vector platform. The lead commercial product is VYJUVEK (beremagene geperpavec-svdt), the first and only FDA-approved redosable gene therapy for dystrophic epidermolysis bullosa (DEB), applied topically to deliver the COL7A1 gene to skin cells. The company also maintains a pipeline of gene therapy candidates for cystic fibrosis, Alpha-1 Antitrypsin Deficiency, lung cancer, neurotrophic keratitis, and other rare diseases, plus an aesthetics subsidiary (Jeune Aesthetics).

Is Krystal Biotech a public or private company?

Krystal Biotech is a public company. It is classified as public and is currently operating.

When was Krystal Biotech founded?

Krystal Biotech was founded in 2016. It employs 251 to 500 people.

Where is Krystal Biotech based?

Krystal Biotech is headquartered in Pittsburgh, United States, in the North America region.

How does Krystal Biotech make money?

One revenue line is on record: VYJUVEK Product Sales.

Who are Krystal Biotech's main competitors?

Direct peers on record are uniQure, Abeona Therapeutics, Rocket Pharmaceuticals, Sarepta Therapeutics, CRISPR Therapeutics and bluebird bio. Broad incumbents are Vertex Pharmaceuticals, Regeneron Pharmaceuticals and BioMarin Pharmaceutical. Ultragenyx Pharmaceutical is listed as an emerging player.

Does Krystal Biotech have an API?

No public API is recorded for Krystal Biotech.

What industry is Krystal Biotech in?

Krystal Biotech's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAACAE, Gene Therapy for Rare/Monogenic Diseases. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Krystal Biotech, Inc. - KRYSPomerantz LLP is investigating Krystal Biotech for potential securities fraud, following the company's announcement on November 2, 2026, that data releases for several product candidates would be delayed until 2027. The stock fell 10.95% to $295.90 per share on that day. Investors are advised to contact the firm for more information.GlobeNewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Krystal Biotech, Inc. - KRYSPomerantz LLP is investigating Krystal Biotech for potential securities fraud, following the company's announcement on November 2, 2026, that data releases for several product candidates would be delayed until 2027. The stock fell 10.95% to $295.90 per share on that day.Investing.comKrystal Biotech at Jefferies Global Healthcare Conference: global push buildsKrystal Biotech outlined its business at the Jefferies Global Healthcare Conference, citing strong U.S. demand for VYJUVEK with over 760 reimbursement approvals and 60% market share. The company expects international growth to eventually exceed U.S. revenue, with Germany pricing completed and Japan launched. It also highlighted upcoming clinical readouts in 2026-2027.Simply Wall StHow $400 Million Buyback Will Impact Krystal Biotech (KRYS) StockKrystal Biotech reported Q3 2026 net income of $63.07 million and basic EPS of $2.13, and announced a new $400 million share repurchase program with no set end date. The buyback follows nine months of $173.77 million net income and reflects management's focus on cash generation and capital return.Simply Wall StKrystal Biotech (KRYS), What Is Behind The Fresh Attention?Krystal Biotech reported Q3 earnings on November 2 showing continued profitability and announced a $400 million share repurchase authorization. Despite the buyback, the stock is down 7.6% over 30 days and 7.9% over 90 days. Analysts see a fair value of $392.11, but the P/E of 40.3x exceeds the sector average of 16x.Defense WorldKrystal Biotech, Inc. (NASDAQ:KRYS) Stock Now Rated “Moderate Buy” by Wall Street AnalystsKrystal Biotech received an average "Moderate Buy" rating from 14 analysts, with a $375 target price. The company reported Q3 EPS of $2.05, beating estimates, and revenue of $127.34 million. Analysts expect 7.74 EPS for the current year.Simply Wall StWhat Early Krystal Biotech Buyers SawKrystal Biotech's board approved a US$400 million share repurchase, and its stock rose 52% over the past year. Q3 2026 revenue reached US$127.3 million, but net margin fell to 49.5% from 81.2%. The company's fair value estimate remains above current price, citing late-stage pipeline programs.American Banking and Market NewsKrystal Biotech, Inc. (KRYS) – What Are Researchers Saying About This Stock?Krystal Biotech shares received a consensus 'Moderate Buy' rating from 14 analysts, with an average price target of $375. The company reported Q3 EPS of $2.05, beating estimates of $1.79, and revenue of $127.34 million. Analysts forecast fiscal-year EPS of $7.74.TradingViewCitigroup maintains Krystal Biotech at Buy, lowers price target to $412 from $416Citigroup maintained Krystal Biotech at Buy and lowered its price target to $412 from $416. The target implies a 39.2% upside from the Nov 2 close of $295.90. Recent analyst price targets range from $361 to $380.TradingViewRBC Capital maintains Krystal Biotech at Outperform, lowers price target to $375 from $400RBC Capital maintained Krystal Biotech at Outperform and lowered its price target to $375 from $400, a 6.2% decrease. The target implies a 26.7% upside from the Nov 2 close of $295.90.